Abstract Number: 1520 • ACR Convergence 2021
Do Specific Rheumatic Autoantibodies Predict Severity or Time to Onset of Immune-related Adverse Events from Checkpoint Inhibitors?
Background/Purpose: Immune checkpoint inhibitors (ICI) are a novel cancer therapeutic that have had a dramatic impact on treating advanced malignancies by enhancing the anti-tumor T…Abstract Number: 1521 • ACR Convergence 2021
Autoantibody Microarray Signal Intensities May Predict the Occurrence of Immune-related Adverse Events
Background/Purpose: Immune checkpoint inhibitors (ICI) are a novel cancer therapeutic that have had a dramatic impact on treating advanced malignancies by enhancing the anti-tumor T…Abstract Number: 1523 • ACR Convergence 2021
Outcomes and Disease Characteristics in Patients with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors for Malignancy at a Single Academic Institution
Background/Purpose: Since the introduction of the first immune checkpoint inhibitor (ICI) in 2011, they have become widely utilized in the treatment of malignancy. It is…Abstract Number: 0438 • ACR Convergence 2021
Rheumatological Immune-Related Adverse Events of Immune Checkpoint Inhibitors Based on the FDA Adverse Event Reporting System
Background/Purpose: Immune checkpoint inhibitors (ICIs) provide effective treatment for many cancers but, presumably due to persistent activation of the immune system, they cause a variety…Abstract Number: 1516 • ACR Convergence 2021
Clinical Phenotypes and Treatment of Rheumatic Immune-Related Adverse Events from Checkpoint Inhibitors: A Retrospective Cohort of 112 Patients
Background/Purpose: To describe a single center cohort of rheumatic immune related adverse events (irAEs) observed in patients treated with checkpoint inhibitor therapy (ICI) and to…Abstract Number: 1519 • ACR Convergence 2021
Concomitant Targeted Therapy with Ongoing Immune Checkpoint Inhibitor (ICI) Therapy for Severe Immune Related Adverse Events (irAEs): Clinical Experience from Two Centers
Background/Purpose: Treatment of irAEs is a balance of suppressing irAE-associated hyper-inflammation without inhibiting anti-tumoral effects of ICI. Treatment of grade 3/4 irAEs is most challenging…Abstract Number: 2152 • 2019 ACR/ARP Annual Meeting
Safety of Immune Checkpoint Inhibitors in Patients Treated for Cancer with Pre-existing Autoimmune Diseases
Background/Purpose: Patients with pre-existing autoimmune diseases (AID) have been traditionally excluded from clinical trials of immune checkpoint inhibitors (ICI), so the data on risk of…
ACR Meeting Abstracts